HFSA 25 - Sex-specific outcomes of tirzepatide in obesity-related HFpEF showed that at baseline, women with HFpEF had more severe heart failure symptoms.

Dr Barry Borlaug (Mayo Clinic, US) joins us to discuss a prespecified secondary analysis from the SUMMIT trial, examining sex-specific effects of tirzepatide in patients with heart failure with preserved ejection fraction and obesity.

The SUMMIT trial, originally presented at the American Heart Association 2024 Scientific Sessions, established the safety and efficacy of the dual GIP/GLP-1 receptor agonist tirzepatide in patients with obesity-related HFpEF. This prespecified secondary analysis now provides important insights into whether treatment effects differ between male and female patients, a critical consideration given the epidemiology of HFpEF and known sex differences in obesity, metabolic syndrome, and cardiovascular disease.

Key findings showed that women with obesity-related HFpEF had somewhat more severe heart failure compared to men.

Interview Questions:

1. What is the current landscape for treating obesity-related HFpEF, and why are sex-specific analyses important in this population?
2. What were the aims of this secondary analysis from SUMMIT?
3. What were your key findings regarding differential effects by sex?
4. How do these findings fit with what we know about sex differences in HFpEF and metabolic disease more broadly?
5. What are the clinical implications of these findings for managing patients with obesity-related HFpEF in routine practice?
6. What are your key take-home messages for clinicians, and what are the next steps for research in this area?

Recorded remotely from Rochester, 2025.
Editor: Jordan Rance
Videographer: Oliver Miles
Support: This is an independent interview produced by Radcliffe Cardiology.